NeueHealth EBIT

The latest EBIT for NEUE is $-140M as of June 2025. That compares with $-190M in the prior-year period — up 28.6% year over year. That is below the Finance sector average of $320B. Investors often review this figure alongside NeueHealth's historical trend and sector peers before judging valuation or financial health.

Over the past year, NEUE's EBIT moved from $-190M to $-140M — a 28.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in NeueHealth's operating scale or balance-sheet position.

Against Finance companies, NEUE currently prints $-140M for EBIT, while the sector average sits near $320B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at NeueHealth's growth, margins, and balance sheet.

A EBIT figure of $-140M for NEUE is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Finance average is about $320B. Explore the charts below for those layers of context.

After noting NEUE's EBIT ($-140M), review year-over-year change from $-190M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.